ClinicalTrials.gg
Not yet recruitingNCT07944326RENAISSANCEUpdated Nov 18, 2026

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial

A Phase 3 interventional study of Sotagliflozin and Placebo in Kidney Transplant Recipient, sponsored by University of British Columbia. Not yet recruiting at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of British Columbia · Phase 3, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.

Read the detailed description

RENAISSANCE (Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients) is a pragmatic, prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sotagliflozin in adult kidney transplant recipients (KTRs).

Scientific Background and Rationale

Kidney transplant recipients remain at substantial risk of premature death, cardiovascular disease (CVD), heart failure (HF), and progressive loss of kidney transplant function. Cardiovascular complications are a leading cause of death among KTRs, while progressive deterioration in allograft function remains a major contributor to long-term transplant failure. These cardiovascular and kidney complications are interrelated, with deterioration in either organ system potentially contributing to dysfunction in the other.

Sodium-glucose cotransporter (SGLT) inhibitors have demonstrated cardiovascular and kidney protective effects in individuals with diabetes, heart failure, and chronic kidney disease (CKD), including reductions in cardiovascular events, hospitalization for heart failure, and progression of kidney disease. However, kidney transplant recipients have largely been excluded from previous large randomized clinical trials because of concerns regarding infection, volume depletion, and potential effects on transplant function and rejection. Although small randomized studies and observational data in KTRs suggest potential benefits and an acceptable safety profile, adequately powered randomized evidence is lacking.

RENAISSANCE is designed to address this evidence gap by evaluating whether sotagliflozin can improve long-term cardiovascular and kidney outcomes in KTRs while maintaining an acceptable safety profile.

Study Design and Intervention

Approximately 900 adult kidney transplant recipients will be randomized in a 1:1 ratio to receive either sotagliflozin 200 mg orally once daily or matching placebo. Study treatment will be administered in addition to participants' usual kidney transplant care, including maintenance immunosuppressive therapy and individualized management of cardiovascular risk factors.

Randomization will be stratified according to diabetes status and time since transplantation (less than 5 years versus 5 years or longer). The study will be double-blinded, with participants, investigators, study coordinators, and clinical site personnel unaware of treatment assignment. Active treatment and placebo tablets will be identical in appearance. Treatment allocation will be accessible only to designated unblinded pharmacy and coordinating center personnel, with emergency unblinding available when medically necessary.

Participants will receive study intervention for up to approximately 4.5 years, depending on enrollment timing, and will remain in the study until study closeout. Study medication will be discontinued approximately 4 weeks before the end of the study to allow assessment of kidney function following treatment withdrawal.

Participant Follow-up and Study Procedures

RENAISSANCE incorporates a pragmatic study design intended to minimize participant burden and facilitate participation across geographically diverse populations. Study visits may be conducted in person, by telephone, or through secure video communication, according to participant and investigator preference. Participants are not required to travel to their transplant center for study visits or laboratory testing.

Following randomization and initiation of study medication, participants will have an initial safety assessment approximately 2 to 6 weeks after starting treatment. This assessment includes evaluation of serum creatinine and estimated glomerular filtration rate (eGFR) to monitor kidney function following treatment initiation.

Subsequent study assessments will occur approximately every 3 months, with a 28-day visit window. Assessments will include review of medical history, concomitant medications, study medication adherence, adverse events, weight, and blood pressure. Serum creatinine and other clinically available laboratory results will be collected approximately every 3 months, while urine albumin-to-creatinine ratio will be assessed approximately every 6 months.

Whenever possible, laboratory results and clinical measurements obtained as part of routine transplant care will be used for study purposes to minimize additional testing. Participants may use their local laboratory and healthcare providers, with appropriate authorization for collection of clinical information. If required laboratory assessments are not available through routine care, study-related testing will be arranged.

At the end of the treatment period, kidney function will be assessed at study medication discontinuation and again approximately 4 weeks after discontinuation to evaluate changes following the treatment washout period.

Safety Monitoring and Risk Mitigation

The safety of sotagliflozin in kidney transplant recipients is a central component of the study. Particular attention will be given to potential adverse effects associated with SGLT inhibition, including genital mycotic infections, urinary tract infections, volume depletion, symptomatic hypotension, diabetic ketoacidosis, hypoglycemia, diarrhea, bone fractures, and changes in kidney function. The study will also monitor for acute kidney injury, infections requiring emergency care or hospitalization, kidney biopsy, and biopsy-proven acute transplant rejection.

Participants will receive counseling regarding potential risks and appropriate precautions during treatment. They will be instructed to temporarily hold study medication during periods of acute illness or fasting and during treatment of intercurrent urinary tract or genital yeast infections, in consultation with their healthcare provider and study investigator. Investigators may also coordinate adjustments to concomitant diuretics or glucose-lowering medications when clinically indicated to minimize the risk of volume depletion or hypoglycemia.

Study medication may be permanently discontinued when continued treatment is considered inappropriate for participant safety, including clinically significant adverse events, initiation of dialysis, kidney retransplantation, or pregnancy. Discontinuation of study medication does not automatically result in withdrawal from the study. Participants will be encouraged to continue study follow-up, allowing collection of clinical outcomes and safety information regardless of treatment discontinuation.

Outcome Assessment and Analysis

The study will evaluate the effects of sotagliflozin on major cardiovascular and kidney outcomes, including mortality, kidney transplant failure, cardiovascular events, heart failure events, and changes in kidney function over time. Clinical events, including cause of death, stroke, myocardial infarction, and heart failure events, will be reviewed by an independent adjudication committee blinded to treatment assignment.

The primary efficacy analysis will use a hierarchical composite approach that prioritizes clinically important outcomes, with all-cause mortality and kidney transplant loss ranked above cardiovascular events, sustained decline in kidney function, and heart failure events. Longitudinal kidney function will also be evaluated using eGFR trajectories over the treatment period. Additional analyses will assess cardiovascular and kidney outcomes, metabolic measures, albuminuria, and safety events.

The study will compare outcomes between the sotagliflozin and placebo groups to determine whether treatment provides cardiovascular and kidney protection without an unacceptable increase in adverse events.

02

Conditions studied

  • Kidney Transplant Recipient

Keywords

  • SGLT inhibition
  • kidney transplant recipient
  • cardiovascular protection
  • kidney protection
  • sotagliflozin
03

In context

Lead sponsor

University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. ≥ 6 months post living or deceased donor kidney transplant
  3. Estimated (eGFR) ≥20 ml/min/1.73m2 by the CKD-EPI-creatinine 2021 formula within 28 days prior to randomization.
  4. At increased risk for worsening allograft function or cardiovascular event as defined by one of the following groups:

    1. Type 2 diabetes
    2. ≥ 30 kg/m2
    3. History of post-kidney transplant hospitalization for congestive heart failure (regardless of )
    4. eGFR \<30 ml/min/1.73m2
    5. Albuminuria (UACR ≥ 11.3 mg/mmol or urine protein to creatinine ratio (UPCR) ≥ 500 mg/g) within 28 days of randomization and a second urine sample over the prior two years; the rationale for this cut-point is that given the patient-centered study design, we are not necessitating first morning voids and random urine specimen albumins are usually higher than first morning samples.
    6. History of CV event (myocardial infarction, stroke)
    7. At risk for CV event (history of coronary artery bypass, percutaneous coronary intervention, peripheral artery bypass or stent, or age ≥50yr (men) or ≥60yr (women) with at least two additional risk factors: hypertension, hyperlipidemia or current smoker (see MOP for definitions of hypertension and hyperlipidemia).
  5. Ability of the participant or Legally Authorized Representative to understand and sign a written .
  6. Ability to comply with all components of the study

Exclusion criteria

Exclusion Criteria:

  1. SGLT inhibitor use in the previous 3 months
  2. Type 1 diabetes
  3. Multi-organ or extrarenal transplant (except cornea)
  4. Acute coronary syndrome, or stroke within 1 month prior to screening
  5. Suspicion for acute rejection and/or plans for kidney
  6. Acute rejection within 3 months prior to screening
  7. Ongoing treatment for rejection
  8. Acute kidney injury (AKI) in the last 3 months (may be rescreened)
  9. History of diabetic ketoacidosis in the last 5 years
  10. High risk for urinary tract infection (UTI) (e.g. need for indwelling or recurrent catheterization, or frequent (>3 per year) UTIs)
  11. Active treatment for BK nephropathy, Cytomegalovirus viremia, Epstein Barr Virus viremia
  12. Active treatment for recurrent/post-transplant glomerulonephritis
  13. Severe hepatic impairment ( class C)
  14. Current treatment with rifampicin
  15. Pregnancy, lactation or women of * unless taking adequate precautions to avoid the possibility of becoming pregnant (as defined in the manual of procedures) until 4 weeks after the last dose of study drug
  16. Known allergic reactions to components of sotagliflozin
  17. Current treatment with another drug or device
  18. Incarcerated individuals
  19. History of any other acute or chronic medical condition (e.g., urogenital abnormalities) or pre-planned surgical procedure that in the opinion of the investigator would compromise the safety of the patient or the integrity of the study results.

    • A woman of child-bearing potential is defined as a participant who has:

      • Experienced menarche and engages in activity that involves penile-vaginal intercourse with a partner capable of causing pregnancy AND
      • Has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy/oophorectomy) or is not (≥12 consecutive months of spontaneous amenorrhea without an alternative medical cause).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Sotagliflozin

    Drug: Sotagliflozin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.

    Also known as: LX4211

  • DrugPlacebo

    Matching placebo will be administered for 3-4.5 years.

06

What researchers measure

Primary outcomes

  1. Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR Slope

    A hierarchical composite endpoint consisting of the following components, ranked in order of clinical importance: 1. All-cause mortality. 2. Kidney transplant loss, defined as chronic dialysis for more than 90 days, retransplantation, or sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months. 3. Non-fatal stroke or non-fatal myocardial infarction (MI). 4. Sustained 40% decline in estimated glomerular filtration rate (eGFR) from screening, confirmed by two creatinine measurements obtained at least 3 months apart. 5. Heart failure (HF) events, defined as hospitalization for HF or urgent treatment for HF. 6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the last on-study drug visit and expressed in mL/min/1.73 m²/year. The hierarchical composite will compare treatment groups according to the prespecified ranking of these outcomes.

    Time frame: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.

  2. Number of Participants Experiencing Serious Adverse Events

    Number of participants experiencing one or more serious adverse events (SAEs) during the study. Serious adverse events will be defined according to the applicable regulatory criteria for seriousness.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  3. Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug Discontinuation

    Number of participants who permanently discontinue the assigned study drug due to an adverse event.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  4. Number of Participants Experiencing Study Drug-Related Adverse Events

    Number of participants experiencing at least one adverse event considered related to the study drug by the investigator.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  5. Number of Participants Experiencing Adverse Events of Special Interest

    Number of participants experiencing at least one adverse event of special interest (AESI) during the study period. Adverse events of special interest include: * Genital mycotic infections * Urinary tract infections * Infectious complications requiring an emergency department visit or hospitalization * Amputations * Bone fractures * Diabetic ketoacidosis * Symptomatic hypotension * Symptomatic hypoglycemic episodes * Diarrhea * Kidney biopsy * Biopsy-proven acute rejection Each adverse event will be assessed and recorded throughout the study. Participants experiencing one or more adverse events of special interest will be counted in this outcome measure.

    Time frame: From randomization to the end of the study (up to 4.5 years).

Secondary outcomes

  1. Number of Participants Experiencing All-Cause Mortality

    Number of participants who die from any cause during the study period.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  2. Number of Participants Experiencing Kidney Transplant Loss

    Number of participants experiencing kidney transplant loss, defined as any of the following: * Requirement for chronic dialysis for more than 90 days. * Kidney retransplantation. * Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  3. Number of Participants Experiencing Non-Fatal Stroke or Non-Fatal Myocardial Infarction

    Number of participants experiencing a non-fatal stroke or non-fatal myocardial infarction during the study period.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  4. Number of Participants Experiencing a Sustained 40% Decline in eGFR

    Number of participants experiencing a sustained decline of 40% or greater in estimated glomerular filtration rate (eGFR) from screening. The decline must be confirmed by two serum creatinine measurements obtained at least 3 months apart.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  5. Number of Participants Experiencing Heart Failure Hospitalization or Urgent Heart Failure Treatment

    Number of participants experiencing a heart failure event, defined as hospitalization for heart failure or urgent treatment for heart failure.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  6. Total eGFR Slope from Screening to the End of Study Drug Treatment

    The total eGFR slope represents the rate of change in estimated glomerular filtration rate (eGFR), expressed in mL/min/1.73 m²/year. It will be calculated using longitudinal eGFR measurements obtained from screening to the end of study drug treatment.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  7. Hierarchical Composite of Kidney Death, Kidney Transplant Loss, Sustained 40% Decline in eGFR, and Total eGFR Slope

    A hierarchical composite kidney endpoint consisting of the following components: 1. Kidney death. 2. Chronic dialysis for more than 90 days. 3. Kidney retransplantation. 4. Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months. 5. Sustained 40% decline in eGFR from screening, confirmed by two serum creatinine measurements obtained at least 3 months apart. 6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment and expressed in mL/min/1.73 m²/year. The components will be evaluated according to their prespecified hierarchical ranking.

    Time frame: From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.

  8. Hierarchical Composite of Cardiovascular Death, Non-Fatal Stroke, Non-Fatal Myocardial Infarction, and Heart Failure Events

    A hierarchical composite cardiovascular endpoint consisting of the following components: 1. Cardiovascular death. 2. Non-fatal stroke. 3. Non-fatal myocardial infarction. 4. Heart failure events, defined as hospitalization for heart failure or urgent treatment for heart failure. The components will be evaluated according to their prespecified hierarchical ranking.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  9. Number of Participants Experiencing Cardiovascular Death

    Number of participants who die due to cardiovascular causes during the study period.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  10. Number of Participants Experiencing Kidney Death

    Number of participants who die due to kidney-related causes during the study period.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  11. Total eGFR Slope from Screening to the End of Study Drug Treatment

    The total eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment.

    Time frame: From screening to the end of study drug treatment (up to 4.5 years).

  12. Chronic eGFR Slope from 3 Months Post-Randomization to the End of Study Drug Treatment

    The chronic eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements beginning 3 months after randomization and continuing to the end of study drug treatment.

    Time frame: From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).

  13. Comprehensive eGFR Slope from Screening to the End of the Study Washout Period

    The comprehensive eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening through the end of the study washout period.

    Time frame: From screening to the end of the study washout period (up to 4.5 years).

Other outcomes

  1. Number of Participants Developing New-Onset Diabetes

    Number of participants without diabetes at baseline who develop new-onset diabetes during the study period.

    Time frame: From randomization to the end of the study (up to 4.5 years).

  2. Change from Baseline in Body Weight Over the Study Drug Treatment Period

    Change in body weight, measured in kilograms, from baseline (pre-randomization) to the end of study drug treatment. Body weight will be measured at the scheduled study visits to assess changes over time.

    Time frame: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).

  3. Number of Participants Permanently Discontinuing Study Drug

    Number of participants who permanently discontinue their assigned study drug before the planned end of study drug treatment.

    Time frame: From randomization to the end of study drug treatment (up to 4.5 years).

  4. Change from Baseline in Urine Albumin-to-Creatinine Ratio Over the Study Drug Treatment Period

    Change in urine albumin-to-creatinine ratio (UACR) from baseline (pre-randomization) to the end of study drug treatment. UACR will be measured using urine albumin and creatinine concentrations and expressed in mg/g (or the units specified by the laboratory). Measurements at scheduled study visits will be used to assess the trajectory of UACR over time.

    Time frame: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).

  5. Number of Participants Experiencing Acute Kidney Injury

    Number of participants experiencing at least one episode of acute kidney injury during the study period, according to the prespecified diagnostic criteria.

    Time frame: From randomization to the end of the study (up to 4.5 years).

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2027; primary completion for Oct 2031, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 18, 2026
StartEst.
Apr 1, 2027
Primary completionEst.
Oct 1, 2031
CompletionEst.
Mar 1, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944326
Responsible party
Vikas Sridhar (Clinical Assistant Professor of Medicine, University of British Columbia) — Principal investigator
First posted
Nov 18, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Oct 1, 2031 (estimated)
Completion
Mar 1, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Luxcia Kugathasan, PhD
Contact
luxcia.kugathasan@uhn.ca
416-340-4800 ext. 8508
Vikas S Sridhar, MD PhD
principal investigator · University of British Columbia
David ZI Cherney, MD PhD
principal investigator · University Health Network, Toronto
Steve Chadban, BMed(hons) PhD
principal investigator · Royal Prince Alfred Hospital, Sydney, Australia
John Gill, MD MS
principal investigator · University of British Columbia
Arthur Matas, MD
principal investigator · University of Minnesota (Minneapolis)
Amy Mottl, MD MPH FASN
principal investigator · University of North Carolina, Chapel Hill
Deirdre Sawinski, MD
principal investigator · Weill Medical College of Cornell University
Sunita KS Singh, MD MSc
principal investigator · University Health Network, Toronto
David Vock, PhD
principal investigator · University of Minnesota (Minneapolis)
Erika Helgeson, PhD
principal investigator · University of Minnesota (Minneapolis)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion